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Background: Intensive care units (ICU) are epicenters for the emergence of antibiotic-resistant Gram-negative
bacteria (ARGNB) because of high rates of antibiotic usage, rapid patient turnover, immunological susceptibility of
acutely ill patients, and frequent contact between healthcare workers and patients, facilitating cross-transmission.
Antibiotic stewardship programs are considered important to reduce antibiotic resistance, but the effectiveness of
strategies such as, for instance, antibiotic rotation, have not been determined rigorously. Interpretation of available
studies on antibiotic rotation is hampered by heterogeneity in implemented strategies and suboptimal study
designs. In this cluster-randomized, crossover trial the effects of two antibiotic rotation strategies, antibiotic mixing
and cycling, on the prevalence of ARGNB in ICUs are determined. Antibiotic mixing aims to create maximum
antibiotic heterogeneity, and cycling aims to create maximum antibiotic homogeneity during consecutive periods.
Methods/Design: This is an open cluster-randomized crossover study of mixing and cycling of antibiotics in eight
ICUs in five European countries. During cycling (9 months) third- or fourth-generation cephalosporins, piperacillin-
tazobactam and carbapenems will be rotated during consecutive 6-week periods as the primary empiric treatment
in patients suspected of infection caused by Gram-negative bacteria. During mixing (9 months), the same antibiotics
will be rotated for each consecutive antibiotic course. Both intervention periods will be preceded by a baseline
period of 4 months. ICUs will be randomized to consecutively implement either the mixing and then cycling
strategy, or vice versa. The primary outcome is the ICU prevalence of ARGNB, determined through monthly
point-prevalence screening of oropharynx and perineum. Secondary outcomes are rates of acquisition of ARGNB,
bacteremia and appropriateness of therapy, length of stay in the ICU and ICU mortality. Results will be adjusted for
intracluster correlation, and patient- and ICU-level variables of case-mix and infection-prevention measures using
advanced regression modeling.
Discussion: This trial will determine the effects of antibiotic mixing and cycling on the unit-wide prevalence of
ARGNB in ICUs.
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Figure 1 All 8 intensive care units (ICUs) start with 4 months
standard care and then perform both interventions: cycling
then mixing or vice versa. ICUs are randomized to start with either
cycling or mixing. After 9 months of intervention and a 1 month
standard care wash-out period, the ICUs cross over into the second
intervention for the final 9 months.
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Infections caused by Gram-negative bacteria frequently
complicate treatment of critically ill patients in the in-
tensive care unit (ICU). Such ICU-acquired infections are
associated with higher morbidity and mortality [1]. The
severity of illness in these patients often precludes await-
ing diagnostic microbiology results. Treatment is therefore
mostly empiric, covering a broad range of potential patho-
gens, increasing selective pressure for antibiotic-resistant
bacteria.
As a response, antibiotic stewardship programs aim to
optimize the rational and prudent use of antibiotics. These
programs attempt to reduce selective pressure by reducing
overall antibiotic consumption, but also to optimize the
choice of the antibiotic, dosing and administration route.
As such, antibiotic rotation has been proposed to reduce
antibiotic resistance through systematically rotating antibi-
otics or antibiotic classes for empirical treatment.
There are two types of rotation schemes: mixing and
cycling. In mixing, the treatment is changed with every
new antibiotic course, and in cycling, empiric antibiotics
change per time block (weeks or months). These interven-
tions have been evaluated in ICUs, but also in neonatal-,
pediatric-, oncology- and cardiothoracic-surgery depart-
ments [2-23]. The methodology of these studies and the
results obtained, however, vary widely. Importantly, study
design, data collection and statistical analyses did not al-
ways take into account clustering of antibiotic resistance
within ICUs, confounding by antibiotic use and changes
in case-mix or infection prevention measures [24].
This multicenter cluster randomized crossover trial
was designed to determine the effects of mixing and cyc-
ling of antibiotics in eight European ICUs, incorporating
the most relevant confounders and adjusting for cluster-
ing of results in the analysis. For uniformity of reporting,
we have used the CONSORT 2010 statement: extension
to cluster randomized trials [25].
Study objectives
The primary objective of this trial is to compare the effects
of a strategy of antibiotic mixing (rotation of empirical
antibiotic treatment per next individual patient) to a strat-
egy of antibiotic cycling (preferred empirical antibiotic
treatment changes every 6 weeks) on the mean unit-wide
prevalence of antibiotic-resistant Gram-negative bacteria
(ARGNB). The primary hypothesis is superiority of one
intervention arm over the other.
Methods/Design
Study design
The trial has a cluster-randomized, crossover design. All
ICUs start with a 4-month standard care period with no
interventions and are then randomized to one of two in-
terventions of 9 months. After a wash-out period of 1month, the ICUs cross over and perform the alternate
rotation strategy for a second 9-month period (Figure 1).
Inclusions will start January 2011 and the last ICU will
finish February 2014.
Participants
The participating ICUs are the primary object of study, in-
dividual data of all admitted patients will be used for sec-
ondary endpoints. Inclusion criteria for ICUs are listed in
the “Intensive care unit inclusion criteria” section. ICUs
have been selected through a tendering procedure accord-
ing to EU regulations. An open tender communiqué was
sent to hospitals directly and published on public websites
of the European Society of Clinical Microbiology and In-
fectious Diseases and the European Society of Intensive
Care Medicine. Interested ICUs were screened through
questionnaires and on-site visits to assess eligibility.
Thirty-eight ICUs showed an interest, of which eight
ICUs in five countries were selected (in Belgium, France
(n = 2), Germany (n = 2), Portugal and Slovenia (n = 2)).
For all ICUs, IRB approval that required a waiver for in-
dividual patient written informed consent was obtained.
The SATURN ICU trial was registered in the Clinical-
Trials.gov (NCT01293071).
Intensive care unit inclusion criteria
Inclusion criteria
1. At least eight beds with capacity of mechanical
ventilation
2. Presence of at least one research nurse (or
equivalent personnel) dedicated to the trial
3. Facilities for storage of screening swabs at -70
degrees Celsius
4. Approval of study protocol by the local Institutional
Review Board (IRB)
5. Ability to obtain an informed consent waiver for
individual patients
6. Ability to obtain written consent by physician and
nursing staff representative to participate in the trial
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system for data extraction
8. No planned implementation of other interventions
that may affect resistance prevalence during the
study period
9. Not being an Intensive Care Burn Unit,
Cardiothoracic Surgery Unit, Pediatric Intensive
Care Unit, or Neonatal Intensive Care Unit
Interventions
During the intervention periods, the ICU-wide preferred
empirical treatment for ICU-acquired infections with
Gram-negative bacteria is rotated according to two pro-
tocols; mixing and cycling. The three rotated antibiotics
will be 1) third- or fourth- generation cephalosporins, 2)
piperacillin-tazobactam and 3) carbapenems.
During mixing, the preferred choice for empiric anti-
microbial treatment changes with every newly prescribed
empiric antibiotic course. During cycling, empiric treat-
ment changes every 6 weeks. The order of interventions
and the order of rotated antibiotics are randomized at
the beginning of the trial by a person not involved in the
design or execution of the study.
Treating physicians can deviate from study protocol at
any point and for any reason because of patient safety or
as part of de-escalation of antibiotic treatment. Combin-
ation therapy with preferred antibiotics (such as addition
of an aminoglycoside or coverage of Gram-positive bac-
teria) is allowed. ICU-specific procedures related to stand-
ard hygienic measures, monitoring practices, outbreak
management and any other infection prevention measures
will not be dictated by study protocol.
Overall antibiotic use will be derived from ward-level
consumption based on either individual prescription
data or weekly unit level administrative antibiotic data.
As a proxy for protocol adherence, weekly point-
prevalence measurements of antibiotic consumption will
be taken. Antibiotic courses are then counted, regardless
of dose or route of administration. The counts will then
be translated to fractions of study-adherent antibiotics of
all antibiotics. With optimal adherence, the three preferred
antibiotics should be in equal proportions during mixing,
whereas the preferred antibiotic should be dominant dur-
ing cycling. Weekly graphs of ICU-specific results are then
returned to each of the ICUs to provide compliance
feedback.
Outcomes
The primary endpoint is the mean ICU-level point-
prevalence of ARGNB, which will be obtained by combin-
ing the nine monthly point-prevalence screening results for
each study period. Unit-wide monthly point-prevalence sur-
veys will be performed by obtaining swabs from oropharynx
and perineum from all patients present in the ICU duringthe point-prevalence survey. Swabs will be frozen dir-
ectly and analyzed in a central microbiology laboratory
(Appendix). Resistance is defined as extended-spectrum
beta-lactamase (ESBL)-producing Enterobacteriaceae,
Piperacillin-Tazobactam resistance in Enterobacteriaceae,
Pseudomonas aeruginosa and Acinetobacter species, and
Carbapenem resistance in P. aeruginosa and Acinetobacter
species (Table 1).
Secondary endpoints are: 1) individual patient acquisi-
tion rates of ARGNB per admission days at risk; defined
as the first positive culture for ARGNB >48 hrs after ad-
mission. 2) ICU-acquired bacteremia rates with ARGNB
per admission days at risk; 3) percentage of appropriate
empirical treatment of ICU-acquired bacteremia; 4) mean
length of stay in ICU; and 5) mean in-ICU-mortality.
For these secondary outcomes, clinical culture results
will be used to determine ARGNB colonization status.
Appropriateness of empirical treatment will be based on
blood culture isolate antibiograms and antibiotic treat-
ment prescribed. Length of ICU stay and in-ICU mortal-
ity will be derived from computerized patient records.
Sample size calculation
Sample size calculations for individually randomized pa-
tients assume that patient outcome is independent of
other patients’ outcomes, an assumption that is frequently
violated when investigating the dynamics of infectious dis-
ease. Ignoring this interpatient dependency may lead to
overestimation of treatment effect and underestimation of
the necessary sample size.
The calculated sample size without clustering is 392
cultured patients per intervention arm, assuming a bino-
mial distribution and based on 80% power to detect an
absolute change of 10% in resistance prevalence with a
95% confidence level using a two-sided test. The sample
size is based on a worst-case scenario with regard to pre-
cision; the widest distribution and thus largest needed
sample size is around 50% for a binomial distribution.
Therefore, the prevalence decrease was set from 55% to
45%. As an illustration, to detect a reduction from 30%
to 20%, 291 patients per intervention period are needed.
To include clustering effects we used an Intra-class Cor-
relation Coefficient (ICC) of 0.01, based on a previous
cluster-randomized ICU study [26]. For estimation of
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ICU had 15 beds for every 9-month-prevalence meas-
urement, resulting in 135 samples per ICU, per inter-
vention arm, which yields a design effect of 2.35 [25].
Multiplying the unadjusted sample size of 392 with the
design effect means 921 sampled patients for one arm,
and that 1,842 for both intervention arms are needed.
With an expected 2,160 sampled patients for both
intervention arms (2 times 9 point-prevalence measure-
ments in eight 15-bed ICUs), our study should therefore
be adequately powered.
Data collection
Dedicated staff will collect data from (digital) patient charts
and microbiology reports. Screening swabs will be collected
by qualified personnel, either by the ICU-staff or study-
nurse. Data of potential confounders is collected from com-
puterized individual patient records (for example, age,
gender, admission diagnosis). Ward-specific confounder
data (such as hand hygiene compliance, use of indwelling
devices, use of isolation measures, and staffing ratios) are
obtained from monthly point-prevalence measurements.
Weekly point-prevalence measurements of antibiotic
consumption will be collected either directly on the
ward or from the patient data management system.
Analysis
Two types of outcome analysis will be performed: ana-
lysis of the ICU-level of resistance prevalence (primary
outcome) and analyses on individual patient level, in-
cluding the secondary outcome measures (Table 2).
Descriptive analysis will be performed of baseline
characteristics and covariates. Where appropriate, bivari-
ate tests will be performed. Bivariate statistical testing
and advanced regression analysis will be used to model
the effect of the interventions on resistance prevalence
and acquisition. This will include adjusting, if necessary,
for clustering of outcome data and confounding within
ICUs by patient demographics, antibiotic consumption, ill-
ness severity, infection prevention measures and time
trends. Results from point-prevalence measurement will
be analyzed as continuous or count measurements perTable 2 Summary of analyses for secondary outcomes
Outcome Ana




Intensive care unit (ICU)-acquired bacteremia rates McN
ICUs
Percentage of appropriate empirical treatment of ICU-acquired
bacteremia
McN
Mean length of stay in ICU Paire
In-ICU mortality McN
ICUsICU for each intervention period, taking auto-correlation
within ICUs into account in regression analysis.
The primary outcome measurements will be analyzed
using McNemar’s test for dependent pairs with all out-
comes pooled for mixing or cycling. Bivariate tests, how-
ever, do not take into account differences in effects
between hospitals, trends over time or possible confound-
ing. Therefore, a stepwise mixed effects model will be con-
structed using the prevalence of resistance colonization as
outcome, and the interventions as a factor. To assess dif-
ferences in treatment effects between ICUs and time
trends over study periods, random effects for the eight
ICUs and the nine longitudinal measurements per ICU
per study period will be added stepwise to the model. In
the case of an imbalanced case-mix between interventions,
confounders can be added to the model to adjust for these
differences. This will facilitate adjustment for intracluster
correlation and for imbalances in the study arm case mix
(patient and ICU characteristics) not caused by the inter-
ventions themselves.
For the secondary outcomes, analyses are stated in
Table 2. For acquisition rates of ARGNB, bacteremia
with resistant Gram-negative bacteria, and mortality, the
McNemar’s test for dependent pairs will be performed
first, followed by the Cox-proportional hazard regression
models, accounting for differences in time-at-risk, inter-
ICU intervention effect differences and possible cofound-
ing. For the proportion of patients receiving appropriate
empirical treatment, the same bivariate test and the same
type regression model is used as for the primary outcome
and by the same argumentation. Mean length of ICU-stay
will be tested using the t-test for dependent means and if
necessary with linear mixed effects regression, again with
inclusion of random effects for individual ICUs and asses-
sing possible confounding.
Because of the crossover design, period effects and
carry-over effects will be assessed.
Discussion
Previous studies
The association between antibiotic use and selective pres-
sure for ARGNB, together with the incomplete evidencelysis
emar’s test; Cox proportional hazard regression with random effects for
.
emar’s test; Cox proportional hazard regression with random effects for
.
emar’s test; Generalized linear regression with random effects for ICUs.
d t-test; Generalized linear regression with random effects for ICUs.
emar’s test; Cox proportional hazard regression with random effects for
.
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rants more research on this subject. The lack of a consist-
ently applied methodology to study antibiotic rotation
strategies, and the suboptimal designs applied in some
studies, seriously hamper interpretation of available results
at present [24]. We have addressed these issues in our
current study, attempting to maximize protocol adherence
and generalizability for European ICUs (Table 3). None-
theless, this unavoidably led to compromises with regard
to interventions, study design and analyses.
Selection of antibiotics, timing of interventions and
outcome measures
We decided to target currently important pathogens,
ARGNB, and the antibiotics mostly used for those in-
fections. Consequently, the used antibiotic classes will be
all beta-lactam antibiotics (in the case of piperacillin-
tazobactam, in combinations with a beta-lactamase inhibi-
tor). It could be hypothesized that rotation of antibiotics
with different mechanisms of action would increase the
effects of mixing and/or cycling. However, given the
current increase in incidence of ESBL-producing bacteria
and resistance to fluoroquinolones, choices of empiric an-
tibiotics have become limited in the different regions of
Europe. A too-specific choice of antibiotics would prevent
inclusion of representative European ICUs, and would,
therefore, reduce generalizability of findings. Indeed, the
antibiotic strategies evaluated in this study may not be
relevant for settings with much lower levels of ESBL-
producing bacteria or in settings with endemicity of
carbapenem-resistant Enterobacteriaceae.
The optimal timing of cycling interventions is as of
yet unknown, and periods of weeks to months have been
used in previous studies [2-18,20-22,27], and studies using
mathematical modeling also did not reach definiteTable 3 Methodological characteristics and key points
Study design feature Advantages D
Cluster allocation Prevents allocation bias Su
flu
Prevents between-intervention cor-








Pre-intervention control period Enables comparison with standard





Crossover Intervention comparison within





timconclusions as to which rotation timing is optimal [28-37].
The studied intervention types include cycling and mixing,
but dynamic and hybrid interventions have also been pro-
posed: using prevalence data when to switch and when to
use either cycling or mixing [37].
We decided to use cycling periods of 6 weeks, to
evaluate reintroduction of the intervention antibiotics.
Six-week periods allow two complete cycles of three an-
tibiotics in 9 months. The aim of this reintroduction is
to investigate possibly faster re-emergence of antibiotic
resistance during the second cycle of antibiotics.
The monthly ICU-level, point-prevalence measurements
will provide unbiased data for ARGNB prevalence. Fur-
thermore, clinical culture results provide additional spe-
cific, though less sensitive, colonization incidence data.
Study design
The open cluster randomized design with a baseline
period and crossover of interventions has methodo-
logical advantages but also limitations over the quasi-
experimental before-after design or patient randomized
studies.
First, the cluster design, with interventions applied unit-
wide, prevents allocation bias within ICUs and reduces
contamination of intervention effects. With individual
patient randomization, different interventions will be
executed in the same ICU at the same time. The transmis-
sibility of infectious disease implies that colonization rates
for patients in the same ward will become dependent,
which may well decrease outcome differences between in-
terventions. A cluster-randomized study design physically
separates the two intervention populations and thereby
prevents transmission-based dependency in resistance
outcomes. Possible associations between resistance ac-
quisition within an ICU are now associated with onlyisadvantages Remarks
sceptible to case mix
ctuations in time









Does not differ between interventions
o control group
arallel in time
Comparable parallel groups/intensive care units
(ICUs) not available, are expected to have
higher heterogeneity in ICU characteristics than
within-ICU comparisons using a crossover
design
creases trial time-span
d effect of baseline
sistance increases over
e
Addressed with time-trend analysis using pre-
intervention control period





Oxoid Brilliance™ ESBL Agar
MacConkey/Ceftriaxone Ceftriaxone (0.5 mg/L)
MacConkey/Pip-Tazo Piperacillin-Tazobactam (4 mg/L)
MacConkey/Carbapenem Meropenem (0.125 mg/L)
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of clustering, or correlation of results within ICUs,
which needs to be accounted for in sample size calcula-
tions and analysis.
Due to the consecutive inclusions in cluster random-
ized studies, these are more susceptible to chance fluctu-
ations potentially causing selection bias, which needs to
be assessed and adjusted for, if present.
Second, the open design may lead to allocation bias,
where certain patient groups will not be eligible for the
treatment with the preferred study antibiotic. Hospital
specific distributions of parameters such as treatment indi-
cation and/or comorbidities will therefore influence adher-
ence and possibly the effect of interventions, depending on
the intervention phase and preferred antibiotic. The cross-
over design, however, will prevent differential distribution/
bias between intervention groups. Nevertheless, the differ-
ent interventions could have implications for adherence still
causing bias between interventions with regard to interven-
tion effect. Assessing differences in intervention adherence
is therefore part of the analysis.
Third, both baseline antibiotic use -and resistance
prevalence are known to change over time, even with-
out interventions such as antibiotic rotation. Baseline
study periods allow quantification of the effects of both
interventions on overall antibiotic use and resistance
prevalence, and extend the possibilities for time-trend
analysis, given the absence of an adequate parallel con-
trol group in time. It was decided not to include such a
parallel control group because of the large differences
of patient populations between ICUs, even within the
same country.
Fourth, the crossover of interventions provides adjust-
ment for differences between units that may also affect
the prevalence of ARGNB.
Finally, with regard to outcome data collection, central-
ized processing of samples will prevent hospital specific
differences in detection of resistance. Admission and dis-
charge swabs are not obtained, making this study less
suited to determine acquisition of cross-transmission rates
of ARGNB.
Sample size and statistical analysis
To our knowledge, this will be the first multicenter
study with eight ICUs on these interventions aiming to
include approximately 10,000 patients in five different
countries [38]. The power calculation included adjust-
ment for intracluster correlation and provides precision,
accuracy and external validity.
The intraclass correlation coefficient (ICC) was used
based on mortality data from a multicenter study in 13
Dutch ICUs. The ICC could therefore be different for anti-
biotic resistance data, which would change the power of
our sample size. Nonetheless, with our current estimatedsample size, the ICC could increase 60% to 0.016. In
addition, this calculation does not account for the cross-
over design, ignoring the reduction in interclass correl-
ation resulting from this design.
Also, the sample-size calculation assumed a similar
ICC for all ICUs, did not take clustering of results ob-
tained on the same sampling day into account, and the
ICC did not include a reported standard error, as recom-
mended in the CONSORT statement.
Outlining the analysis plan, descriptive analysis and
exploration of covariates will precede final regression
analysis. In general terms, the prevalence during both
interventions and secondary outcomes will be com-
pared, assessing whether any - and which of the two in-
terventions - is superior over the other. The baseline
periods will be used to compare standard care to the
intervention periods. The predefined analysis will in-
clude bivariate testing and stepwise methods adjusting
for possible influences of the study design and time effects.
This includes clustering of outcome data, time trends and
confounding using Generalized Linear Mixed Models.
Secondary outcomes will be analyzed using bivariate test-
ing, and Cox-proportional hazard models also accounting
for random effects.
Conclusion
Better understanding of the associations between anti-
biotic pressure and resistance emergence is needed and
important. This trial will provide further insight in the
use of mixing and cycling of antibiotics and guide future
practice guidelines and clinical and mathematical model-





Screening swabs from monthly point-prevalence measure-
ments will be taken from oropharynx and perineum of all
patients in the ICU at that time point. Swabs will be put
directly in medium and frozen at -70° Celsius. The swabs
will then be shipped in batches under frozen conditions to
the UMCU laboratory and centrally typed in the UMCU
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cultured on five different plates (Table 4). Plates will be
cultured overnight at 37 degrees Celsius, and morpho-
logically distinct colonies will be selected and typed with
the MALDI-TOF Mass Spectrometry. Resistance typing is
performed with the Phoenix™ Automated Microbiology
System. ESBL positive isolates will be sent to University of
Antwerp (UA), Belgium for confirmation of ESBL-genes.
Acinetobacter, Pseudomonas and Stenotrophomonas spe-
cies will be sent to the Barcelona Centre for International
Health Research (CRESIB), Barcelona, Spain for pheno-
and genotyping.
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